News

The new subsidiary will be focused on accelerating the commercialization of the Company’s disease detection technology for the healthcare industry.

According to Abbott, with the US launch of their RealTime HIV-1 viral load test physicians now have a reliable test to help ensure that their patients are receiving the most effective treatment.

Aureon Laboratories and their collaborators publish their 'Systems Pathology' model for predicting prostate cancer PSA recurrence in the Journal of Clinical Investigation.

CENiMED, BioTeZ and Invitek announce their cooperation to develop, produce and market the Recovery-ELISAs for the therapy control of humanized antibodies.

Abbott and GE have mutually agreed to terminate their contract for the sale of Abbott’s core laboratory and point-of-care diagnostics businesses to GE.

Delegates representing the 19 member states of the EMBL offered Australia associate membership in EMBL’s international community.

Researchers at the Ontario Institute for Cancer Research have identified a genetic variation on chromosome 8 associated with colorectal cancer.

Roche Diagnostics now owns the patents for Electrochemiluminescence technology and can expand its immunochemistry into new market segments.

UT Southwestern researchers determined how a substance derived from the bark of the South American lapacho tree kills certain kinds of cancer cells.

Weill Cornell researchers have uncovered two new potential points of vulnerability on a key cancer-promoting protein, called XIAP.